The Global Bipolar Disorder Mood Stabilizers Market size was valued at USD 2.22 Billion in 2025 and is expected to reach USD 2.64 Billion by 2032, growing at a compound annual growth rate (CAGR) of 2.5% from 2025 to 2032, as highlighted in a new report published by Coherent Market Insights.
Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/7877
Global Bipolar Disorder Mood Stabilizers Market Key Takeaways
Ø As per Coherent Market Insights (CMI), the global bipolar disorder mood stabilizers market size is set to expand from USD 2.2 Bn in 2025 to USD 2.64 Bn by 2032.
Ø Global demand for bipolar disorder mood stabilizers will likely rise at a sluggish CAGR of 2.5% between 2025 and 2032.
Ø Based on drug type, lithium segment is projected to generate a revenue of over USD 0.78 Bn in 2025.
Ø By indication, bipolar I disorder segment is set to account for nearly one-third of the bipolar disorder mood stabilizers market share in 2025.
Ø Regarding route of administration, oral segment is expected to hold around 2/5 share of the bipolar disorder mood stabilizers market in 2025.
Ø Coherent Market Insights’ latest bipolar disorder mood stabilizers market research predicts North America to account for a prominent market share of 40.3% in 2025. An increase in the prevalence of bipolar disorders due to changing lifestyles and urbanization will likely shape this growth.
Ø Asia Pacific is set to remain a hotbed for bipolar disorder mood stabilizer manufacturers, owing to increasing awareness of bipolar disorders and supportive government initiatives. As per CMI’s latest bipolar disorder mood stabilizers market analysis, the region is set to account for over 1/3 of the global industry share in 2025.
Rising Emphasis on Bipolar Disorder Management Fueling Market Growth
Coherent Market Insights’ latest bipolar disorder mood stabilizers market forecast highlights key factors fueling industry growth. These include rising prevalence of bipolar disorder, increasing diagnosis rates, and growing demand for effective treatments.
Awareness and diagnosis of bipolar disorder have been increasing globally. Advanced diagnostic technologies like neuroimaging, genetic profiling, and AI-driven predictive models are leading to earlier and more accurate diagnoses.
According to the World Health Organization (WHO), around 40 million people are affected by the condition globally. To manage symptoms and reduce the burden, people opt for different medications, including mood stabilizers. This is expected to boost the bipolar disorder mood stabilizers market growth.
Bipolar disorder causes extreme mood swings, including depression and mania. These mood shifts can significantly impact a person’s daily life, behavior, and functioning. To mitigate these mood swings, people use bipolar disorder mood stabilizers like lithium and anticonvulsants.
Also Read: Bipolar Disorder Treatment Market Size, Share & Trends Report (2025-2032)
Side Effects and High Costs Limited Market Growth
The future bipolar disorder mood stabilizers market outlook looks optimistic, supported by increased awareness of bipolar disorders and growing need for effective medicines related to bipolar disorders. However, side effects associated with mood stabilizers and high cost of therapeutic interventions are expected to limit market growth to some extent.
Prolonged use of bipolar disorder mood stabilizers can cause side effects like kidney issues, weight gain, and tremors. These adverse side effects often lead to treatment discontinuation, thereby limiting growth of the bipolar disorder mood stabilizers market.
Branded bipolar disorder mood stabilizers can also be expensive in the long run. This deters patients, especially in lower-income regions, from opting for these medications, thereby lowering the overall bipolar disorder mood stabilizers market demand.
Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/7877
Government Initiatives and Pharmaceutical Innovations Creating Growth Avenues
Governments and healthcare organizations across the world are launching new initiatives and programs to tackle the bipolar disorder burden. This is expected to create lucrative revenue-generation opportunities for the manufacturers of bipolar disorder mood stabilizers.
Top industry players are investing heavily in research and development (R&D) to develop extended-release formulations with improved efficacy and safety profiles. These pharmaceutical innovations will help companies to meet evolving regulatory standards as well as support global market expansions by improving patient compliance and outcomes.
Emerging Bipolar Disorder Mood Stabilizers Market Trends
Ø In the contemporary era, there is growing interest in using personalized medicine to manage mental health conditions. This trend is encouraging pharmaceutical companies to develop more targeted mood stabilizers by using biomarkers and genetic profiling.
Ø Growing popularity of combination therapy is also providing a strong impetus for industry growth. Patients and healthcare professionals are increasingly combining mood stabilizers with antidepressants or antipsychotics to manage symptoms more effectively.
Ø Continuous new drug launches and approvals will play a key role in boosting the overall bipolar disorder mood stabilizers market value. Companies are striving to develop novel and more effective bipolar disorder mood stabilizers.
Ø Industry players are constantly focusing on expediting new drug approvals to address the unmet needs of patients with mental health conditions like bipolar disorder. For instance, in February 2025, the FDA accepted a supplemental NDA for UZEDY, an extended-release injectable suspension, intended for the treatment of Bipolar I Disorder, as per Teva Pharmaceutical Industries Ltd. and Medincell.
Analyst’s View
“The global bipolar disorder mood stabilizers market is poised to grow steadily, driven by increasing prevalence of bipolar disorder, growing need for effective mental health medications, and supportive government initiatives,” said senior analyst Ghanshyam Shrivastava.
Current Events and Their Impact on the Bipolar Disorder Mood Stabilizers Market
|
Event |
Description and Impact |
|
Increasing Prevalence of Bipolar Disorder |
|
|
Advancements in Pharmacological Treatments |
|
|
Digital Health Innovations |
|
Competitor Insights
Key companies in bipolar disorder mood stabilizers market report include:
- AstraZeneca PLC
- Eli Lilly and Company
- AbbVie Inc.
- Johnson & Johnson
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Alkermes plc
- Bristol-Myers Squibb
- Otsuka Pharmaceutical
- GlaxoSmithKline
- Sanofi S.A.
- Takeda Pharmaceutical Company
- Teva Pharmaceutical Industries
- Lundbeck A/S
Key Developments
· In January 2025, Johnson & Johnson announced acquisition of Intra-Cellular Therapies, Inc. to strengthen its neuroscience portfolio. This strategic move aims to enhance Johnson & Johnson's neuroscience portfolio by adding CAPLYTA and other pipeline assets to its offerings.
· In October 2024, AbbVie and Gedeon Richter collaborated on exploring and developing novel targets for neuropsychiatric conditions like bipolar disorder. This collaboration is aimed at creating advanced mental health treatments to address the unmet needs of people with neuropsychiatric disorders.
· In April 2024, the U.S. FDA approved Vanda Pharmaceutical’s drug for the treatment of manic and mixed episodes linked to bipolar disorder.
Get Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/7877
Market Segmentation
Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Others (Combination Therapies, etc.)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Mixed Features Bipolar Disorder
- Rapid Cycling Bipolar Disorder
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral/Injectable
- Transdermal
- Others
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Children and adolescents
- Adults
- Elderly
- Gender
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Also Read: Depression Therapeutics Market Analysis & Forecast (2025-2032)
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
Read Recent Blogs:
https://www.coherentmarketinsights.com/blog
About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter
